09:29 AM EDT, 07/15/2026 (MT Newswires) -- GSK (GSK.L) said Wednesday it completed its acquisition of US-based oncology-focused biopharmaceutical company Nuvalent for $10.6 billion. The acquisition gives the British healthcare giant access to three lung cancer assets, including zidesamtinib and neladalkib, which are undergoing review in the US as potential treatments for variants of non-small cell lung cancer.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.